Bio-based solvents (those derived from biomass) are varied in their sources, but can broadly be classified as either carbohydrate-based by fermentation, carbohydrate-based by pyrolysis and/or chemical methods, essential oil-based, or vegetable oil-based.
A biomass feedstock may be directly transformed into a solvent, such as bio-ethanol by the fermentation of sugars, or limonene by the steam distillation of citrus fruit peels. Some bio-based solvents are obtained after further chemical transformations of bio-based intermediates: dimethyl isosorbide is produced by methylating isosorbide (which in turn is made from hydrogenated glucose).
There are bio-based solvents that have familiar structures and known petrochemical equivalents (ethanol, acetone, ethyl acetate etc.). These bio-based solvents can be introduced into products and processes as direct replacements if their biogenic origin is advantageous (e.g. for labelling or regulatory purposes, or for sustainability reasons). There are many other bio-based solvents with unusual chemical structures that are not easily produced from crude oil. These so-called ‘neoteric’ solvents impart unique combinations of properties that can be advantageous if understood and deployed correctly.
Get familiar with the neoteric bio-based solvents by checking out these infographics!
The neoteric bio-based solvents are often water soluble, high boiling and viscous. As such, the handling and application of these solvents cannot always be the same as conventional solvents. This has generated a lot of interest within academic circles, with work dedicated to overcoming any limitations and excelling in new applications. However, the redesign of large industrial processes to accommodate a viscous (and usually more expensive) solvent for instance is not greeted with the same enthusiasm. This has led to the slow adoption of bio-based solvents and the other categories of neoteric solvents.
The uptake of novel solvents in the pharmaceutical industry is further hindered by regulations. The process by which a pharmaceutical is manufactured is extremely difficult and costly to change once patented and in operation. This means that all reactants and auxiliary chemicals such as the solvents must be obtainable from multiple sources to guarantee the manufacturing process can withstand fluctuations to the price and availability of raw materials. Not only are neoteric bio-based solvents more expensive than traditional solvents, they are often in limited supply with only one producer. This has meant actually using any neoteric solvent on a large scale is perceived as prohibitively risky. However, recent regulatory responses to solvent hazards, and the inherent unsustainability of petrochemical solvents, has called the use of many conventional solvents into question. In time we may see more diverse solvent use within the pharmaceutical industry in order to meet social and regulatory obligations for safe and sustainable chemicals.
Opportunities for bio-based solvents created as petrochemical and fuel products transition towards renewable resources: Clark, J.H., Farmer, T.J., Hunt, A.J. and Sherwood, J., Int. J. Mol. Sci. 2015, 16, 17101-17159.
Advanced biomaterials scenarios for the EU28 up to 2050 and their respective biomass demand: Schipfer, F., Kranzl, L., Leclère, D., Sylvain, L., Forsell, N. and Valin, H., Biomass and Bioenergy 2017, 96, 19-27.
Chemicals and advanced materials: European Commission, 2024.